نتائج البحث - "Juan Martin-Liberal"

1

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

المصدر: Herbst, R S, Arkenau, H T, Santana-Davila, R, Calvo, E, Paz-Ares, L, Cassier, P A, Bendell, J, Penel, N, Krebs, M G, Martin-Liberal, J, Isambert, N, Soriano, A, Wermke, M, Cultrera, J, Gao, L, Widau, R C, Mi, G, Jin, J, Ferry, D, Fuchs, C S, Petrylak, D P & Chau, I 2019, ' Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF) : a multicohort, non-randomised, open-label, phase 1a/b trial ', The Lancet Oncology, vol. 20, no. 8, pp. 1109-1123 . https://doi.org/10.1016/S1470-2045(19)30458-9

مصطلحات موضوعية: Male, 0301 basic medicine, medicine.medical_specialty, Lung Neoplasms, Esophageal Neoplasms, Pembrolizumab, Adenocarcinoma, Antibodies, Monoclonal, Humanized, Gastroenterology, Ramucirumab, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Stomach Neoplasms, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, medicine, Humans, Lung cancer, Adverse effect, Aged, Carcinoma, Transitional Cell, Manchester Cancer Research Centre, Dose-Response Relationship, Drug, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Middle Aged, medicine.disease, 030104 developmental biology, Oncology, Tolerability, 030220 oncology & carcinogenesis, Female, business, Progressive disease

وصف الملف: application/vnd.openxmlformats-officedocument.wordprocessingml.document

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5a4af57c14acaa5521a1f934b805ea8
https://doi.org/10.1016/s1470-2045(19)30458-9

View record from ScienceDirect

Find this article in full text from ProQuest

Full Text via ClinicalKey

2

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

المؤلفون: Sneha Berry, Nicolas Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, Aleksandra Ogurtsova, Abha Soni, Farah Succaria, Daphne Wang, Charles Roberts, Julie Stein, Elizabeth Engle, Drew Pardoll, Robert Anders, Tricia Cottrell, Janis M. Taube, Ben Tran, Mark Voskoboynik, James Kuo, Yung-Lue Bang, Hyun-Cheo Chung, Myung-Ju Ahn, Sang-We Kim, Ayesh Perera, Daniel Freeman, Ikbel Achour, Raffaella Faggioni, Feng Xiao, Charles Ferte, Charlotte Lemech, Funda Meric-Bernstam, Theresa Werner, Stephen Hodi, Wells Messersmith, Nancy Lewis, Craig Talluto, Mirek Dostalek, Aiyang Tao, Sarah McWhirter, Damian Trujillo, Jason Luke, Chunxiao Xu, null BoMarelli, Jin Qi, Guozhong Qin, Huakui Yu, Molly Jenkins, Kin-Ming Lo, Joern-Peter Halle, Yan Lan, Matthew Taylor, Nicholas Vogelzang, Allen Cohn, Daniel Stepan, Robert Shumaker, Corina Dutcus, Matthew Guo, Emmett Schmidt, Drew Rasco, Marcia Brose, Christopher Di Simone, Sharad Jain, Donald Richards, Carlos Encarnacion, James Mier, Jeongshin An, Yeun-yeoul Yang, Won-Hee Lee, Jinho Yang, Jong-kyu Kim, Hyun Goo Kim, Se Hyun Paek, Jun Woo Lee, Joohyun Woo, Jong Bin Kim, Hyungju Kwon, Woosung Lim, Nam Sun Paik, Yoon-Keun Kim, Byung-In Moon, Filip Janku, David Tan, Juan Martin-Liberal, Shunji Takahashi, Ravit Geva, Ayca Gucalp, Xueying Chen, Kulandayan Subramanian, Jennifer Mataraza, Jennifer Wheler, Philippe Bedard

المصدر: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99cf6ca061f4e8a5304f8bf20671ef86
http://link.springer.com/article/10.1186/s40425-019-0519-y

Find this article in full text from ProQuest

3

Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)

المصدر: Annals of Oncology. 30:v454-v455

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::48bdbe222b933c8e5297819da12168d9
https://doi.org/10.1093/annonc/mdz252.011

4

Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma

المؤلفون: Juan Martin-Liberal, Xavier Garcia del Muro, Ezequiel Pérez

المصدر: Expert opinion on investigational drugs. 28(1)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6cae42ea4ace88d99a0e83b21dac659
https://pubmed.ncbi.nlm.nih.gov/30513001

PDF full text from Publisher

5

Encorafenib plus binimetinib: an embarrassment of riches

المؤلفون: Juan Martin-Liberal

المصدر: The Lancet. Oncology. 19(10)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b64434d88af8ce2b21b510634cbe9e54
https://pubmed.ncbi.nlm.nih.gov/30219628

View record from ScienceDirect

Find this article in full text from ProQuest

Full Text via ClinicalKey

6

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study

المؤلفون: Andrés Redondo, Juan Martin-Liberal, Javier Martin-Broto, Nuria Mulet-Margalef, Oscar M. Tirado, Ricardo Cubedo, Xavier Sanjuan, Antonio Lopez-Pousa, Javier Lavernia, Jose A. Lopez-Martin, Xavier Garcia-del-Muro, Javier Martinez-Trufero

المصدر: Targeted Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname